🇺🇸 nicotinic acid/laropiprant in United States

7 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 7

Most-reported reactions

1. Abdominal Discomfort — 1 report (14.29%)
2. Acute Abdomen — 1 report (14.29%)
3. Condition Aggravated — 1 report (14.29%)
4. Dermatitis Allergic — 1 report (14.29%)
5. Flushing — 1 report (14.29%)
6. Small Intestinal Perforation — 1 report (14.29%)
7. Treatment Noncompliance — 1 report (14.29%)

Source database →

Frequently asked questions

Is nicotinic acid/laropiprant approved in United States?

nicotinic acid/laropiprant does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for nicotinic acid/laropiprant in United States?

Manchester University NHS Foundation Trust is the originator. The local marketing authorisation holder may differ — check the official source linked above.